TG Therapeutics announced positive Phase 1 trial results for a new high-concentration subcutaneous formulation of BRIUMVI (ublituximab), showing good safety, tolerability, and effective drug exposure compared to the intravenous form. This subcutaneous version, designed for quarterly self-administration at home, could significantly reduce injection frequency for multiple sclerosis patients and expand the market. The ongoing Phase 3 trial is fully enrolled, with top-line data expected by late 2026 or early 2027, potentially leading to FDA approval in 2028. The results support the potential for a more convenient treatment option for relapsing multiple sclerosis, improving patient experience and access.
TG Therapeutics announced positive Phase 1 results for its subcutaneous Briumvi, demonstrating good bioavailability, safety, and tolerability. This outcome reduces risks for the company's key clinical development program, with Phase 3 topline data ex...
TG Therapeutics published post-hoc data from Phase 3 ULTIMATE I & II trials showing BRIUMVI (ublituximab) significantly reduces annualized relapse rate by 56.7% compared to teriflunomide in treatment-naïve relapsing multiple sclerosis (RMS) patients....
